Celyad Oncology SA
Biotechnology company developing innovative CAR-T cell therapies to treat cancer.
CYAD | BR
Overview
Corporate Details
- ISIN(s):
- BE0974260896 (+2 more)
- LEI:
- 549300ORR0M8XF56OI64
- Country:
- Belgium
- Address:
- RUE ANDRE DUMONT 9, 1435 MONT-SAINT-GUIBERT
- Website:
- https://celyad.com/
Description
Celyad Oncology is a biotechnology company primarily focused on unlocking the potential of its intellectual property in the field of cell therapy. The company discovers and develops innovative technologies for Chimeric Antigen Receptor T-cell (CAR-T) therapies aimed at treating cancer. Its differentiated strategy includes the advancement of proprietary technology platforms and CAR T-cell candidates designed to broaden the range of treatable cancer indications and overcome the main limitations of existing CAR T-cell therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-04 00:00 |
20250904_PR_Double-voting-rights.ENG_Website.pdf
|
English | 154.5 KB | ||
| 2025-09-04 00:00 |
20250904_PR_Double-droit-de-vote.FR_Website.pdf
|
French | 91.2 KB | ||
| 2025-08-26 08:30 |
20250826_PR_R&D discontinuation ENG.FINAL.clean.pdf
|
English | 176.9 KB | ||
| 2025-08-26 08:30 |
20250826_PR_Arret R&D FR.FINAL.pdf
|
French | 162.6 KB | ||
| 2025-08-13 00:00 |
20250913_PR_Fortress Transparency Notification ENG.Final.pdf
|
English | 238.9 KB | ||
| 2025-08-13 00:00 |
20250913_PR_Fortress Transparency Notification FR.Final.pdf
|
French | 224.1 KB | ||
| 2025-08-07 00:00 |
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
|
English | 106.6 KB | ||
| 2025-08-07 00:00 |
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
|
French | 110.9 KB | ||
| 2025-08-07 00:00 |
20250807 PR_Total Number of Voting Rights and Shares_ENG.3.pdf
|
English | 106.6 KB | ||
| 2025-08-07 00:00 |
20250807 PR_Total Number of Voting Rights and Shares_FR.2.pdf
|
French | 110.9 KB | ||
| 2025-08-05 00:00 |
PV Notaire.5août2025.signed.pdf
|
French | 334.3 KB | ||
| 2025-08-05 00:00 |
CELYAD_ Rapport de Commissaire - Augm de K 1 MEUR_VDEF_SIGNED_280725.pdf
|
French | 150.8 KB | ||
| 2025-08-05 00:00 |
FR_Celyad_Rapport Special du CA_PIPE2025_23juillet2025.FE.pdf
|
French | 2.6 MB | ||
| 2025-08-05 00:00 |
20250724_CYAD-PR-PIPE-ENG.2.pdf
|
English | 113.4 KB | ||
| 2025-08-05 00:00 |
20250724_CYAD-PR-PIPE-FR.2.pdf
|
French | 86.4 KB |
Automate Your Workflow. Get a real-time feed of all Celyad Oncology SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celyad Oncology SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celyad Oncology SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-28 | Kane Matthew | Board | Other | 1,035,714 | 279,642.78 EUR |
| 2024-11-26 | Piscitelli Dominic | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-25 | Iserentant Hannes | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-22 | Phan An | Executive member | Other | 30,000 | 8,100.00 EUR |
| 2024-11-06 | Goblet Serge | Board | Other | 10,000 | 2,700.00 EUR |
| 2024-11-05 | Udier Blagovic Marina | Board | Other | 10,000 | 2,700.00 EUR |
Peer Companies
